Knowledge Hub · ¹⁷⁷Lu-DOTATATE
¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy is the most evidence-anchored Lu-177 theranostic in clinical use. NETTER-1 established 20-month median PFS vs 8.4 months on octreotide. NETTER-2 (2024) moved the protocol to first-line. Ga-68 DOTATATE PET picks the responder; post-cycle ¹⁷⁷Lu SPECT/CT verifies the dose actually landed; kidney and bone-marrow dosimetry sets the cumulative ceiling.
Why this matters
NETTER-1 (Strosberg 2017)
The NETTER-1 phase 3 trial randomised midgut NET patients to four cycles of ¹⁷⁷Lu-DOTATATE (7.4 GBq, 8 weeks apart) plus best supportive care vs high-dose octreotide LAR. The Lu-177-DOTATATE arm reached an estimated 65 % progression-free survival at 20 months — vs 11 % on the control arm — and was the registration trial that put PRRT into NCCN, ESMO and EANM guidance.
Based on: Strosberg J et al. Phase 3 trial of ¹⁷⁷Lu-DOTATATE for midgut neuroendocrine tumors. NEJM 2017; 376:125–135.
Read source ↗NETTER-2 (2024)
NETTER-2 moved ¹⁷⁷Lu-DOTATATE to a first-line setting for advanced grade 2 and well-differentiated grade 3 GEP-NETs. Adding Lu-177-DOTATATE to high-dose octreotide tripled median progression-free survival (22.8 vs 8.5 months) and improved objective response rate (43 % vs 9.3 %). PRRT is no longer reserved for octreotide failure — first-line use is now on label.
Based on: Singh S et al. ¹⁷⁷Lu-DOTATATE plus long-acting octreotide vs high-dose long-acting octreotide for the treatment of newly diagnosed advanced grade 2-3 GEP-NETs (NETTER-2). Lancet 2024; 403:2807–2817.
Read source ↗Theranostic pairing
The SSTR2 target seen by Ga-68 DOTATATE PET/CT is the same target hit by ¹⁷⁷Lu-DOTATATE therapy. A Krenning score of 3 or 4 (uptake ≥ liver or ≥ spleen) on pre-therapy PET predicts responder phenotype. Post-cycle ¹⁷⁷Lu SPECT/CT then verifies tumour activity uptake actually reached the lesions imaged. One target, two isotopes, one decision-support chain.
Based on: Bodei L et al. The joint IAEA, EANM, and SNMMI practical guidance on PRRT. EJNMMI 2013; 40:800–816.
Read source ↗Kidney + bone-marrow dosimetry
Renal proximal-tubule reabsorption of the peptide and bone-marrow exposure to circulating activity are the dose-limiting organs in PRRT. Standard amino-acid co-infusion (lysine + arginine) cuts kidney dose ≈30–50 %. Post-cycle ¹⁷⁷Lu SPECT/CT-based dosimetry lets the centre quantify per-cycle kidney and bone-marrow dose and personalise cycle 3 and 4 activity for patients approaching cumulative organ-dose thresholds.
Based on: Sundlöv A et al. Individualised ¹⁷⁷Lu-DOTATATE based on kidney dosimetry. EJNMMI 2017; 44:1480–1489.
Read source ↗n.c.a. starting material
A standard 7.4 GBq PRRT cycle labelled with carrier-added Lu-177 (~600 GBq/mg) requires ~12 mg of cold lutetium in the matrix. The same 7.4 GBq labelled with SHINE-produced n.c.a. Lu-177 (≥3,000 GBq/mg) needs ~2.5 mg. Lower cold-metal mass means cleaner DOTATATE labelling yield, lower peptide load on SSTR2 binding sites, and a tumour-to-background ratio that is not diluted by cold competition.
Based on: Specific activity claims sourced to the SHINE FDA Drug Master File summary.
Read source ↗EANM PRRT practical guidance
EANM PRRT practical guidance frames the 4-cycle × 7.4 GBq × 8-week protocol, the kidney / bone-marrow dosimetry expectations, and the QC dossier (radiochemical purity ≥ 95 %, free peptide < 5 %, endotoxin testing). The Lu-177-DOTATATE labelling SOP plugs into the same EANM framework Indian centres adopt for AERB-licensed theranostic programmes.
Based on: Bodei L et al. EANM procedural guidelines for PRRT with Lu-177 / Y-90 labelled peptides. EJNMMI 2013.
Read source ↗The protocol at a glance
7.4 GBq
Per cycle
Intravenous infusion ≈30 min
4 cycles
Standard course
8-week intervals
22.8 mo
First-line PFS
NETTER-2 grade 2/3
43 %
ORR
NETTER-2 vs 9.3 % control
The NETTER trials, EANM guidance and AERB framework that anchor PRRT in India.
Phase 3 randomised trial of ¹⁷⁷Lu-DOTATATE in midgut NETs — the registration trial for PRRT.
First-line PRRT in advanced grade 2/3 GEP-NETs — moved Lu-177-DOTATATE off the second-line shelf.
European Association of Nuclear Medicine procedural guidelines for Lu-177 / Y-90 PRRT.
Indian framework for Lu-177 sealed / unsealed source import and theranostic-facility licensing.